Rebamipide (Mucosta®), a clinically approved drug, alleviates neuroinflammation and dopaminergic neurodegeneration in a Parkinson’s disease model

Table 1 Molecular docking affinity of rebamipide with NLRP3 inflammasome-associated proteins

Compound	Target protein	Affinity (kcal/mol)
Rebamipide	NLRP3 and NEK7 complex [PDB: 6 NPY]	−10.5
	NLRP3 and NEK7 complex [PDB: 8SXN]	−8.4
	Full-length NLRP3 [Alphafold Model: AF-Q96P20-F1-v4]	−5.5
	Full-length ASC [Alphafold Model: AF-Q9ULZ3-F1-v4]	−4.8
	NALP3 PYD domain [PDB: 3QF2]	−4.8
	ASC CARD domain [PDB: 5H8O] (chain A deletion)	−4.2

ISSN: 1742-2094